CG Results Healthcare advises Sovereign Capital Partners on its investment in Bioscript

  • Service: M&A
  • Sector: Healthcare
  • Sub Sector: Pharma Commercialisation Services
  • Engagement Type: Buy Side
Mar 2021
has invested in

CG Results Healthcare is delighted to announce that it has advised leading UK private equity firm Sovereign Capital Partners on its significant investment in Bioscript, an independent medical communications agency serving international pharmaceutical, biotechnology and medical device companies.

Established in 2005, Bioscript is an international provider of medical communications and regulatory writing services for pharmaceutical companies. Headquartered in the UK and with a team of almost 100, Bioscript assists clients in their communications with regulatory authorities as well as educating the medical sector on pharmaceutical products that are in mid to late-stage clinical trials and subsequently supporting these products, post-market launch, to maintain and grow sales throughout the lifecycle of the drug.

This transaction highlights the value of CG Results Healthcare’s sector knowledge to private equity bidders and cements the firm’s expertise in the healthcare communications sector, following deals including the sale of Cormis Partners to Huntsworth, Unlimited Health’s US division to Next15 and 2e Creative to Fishawack.

CG Results Healthcare are highly regarded for their sector knowledge in medical communications – it was a pleasure to work with them on our investment in Bioscript

Dominic Dalli

Managing Partner, Sovereign Capital Partners

Sector Related Deals

Nov 2021
has received investment from
Aug 2021
a Sovereign Capital Partners-backed company
has acquired
Aug 2021
a Sovereign Capital Partners-backed company
has acquired
Jun 2021
has been acquired by
Apr 2021
has invested in
Jun 2020
has been acquired by
Jun 2020
has been acquired by
Oct 2019
has acquired
Oct 2019
US division
US division, has been acquired by